Form 4: AngioDynamics SVP Warren Nighan Reports Acquisition of Restricted Stock Units and Stock Options

Warren Nighan, SVP of Quality and Regulatory at AngioDynamics, reports the acquisition of restricted stock units, performance rights, and stock options in a Form 4 filing.

Summary

• Warren Nighan, SVP of Quality and Regulatory at AngioDynamics, filed a Form 4 on July 19, 2024, reporting transactions from July 17, 2024.
• Nighan acquired 18,733 shares of common stock in the form of restricted stock units, which vest in four equal annual installments starting July 17, 2025.
• He also acquired 23,952 performance rights, each representing a contingent right to receive one share of common stock, with vesting based on total shareholder return relative to a peer group over a three-year period.
• Additionally, Nighan acquired 23,507 non-qualified stock options with an exercise price of $7.40, vesting in four equal annual installments beginning July 17, 2025, and expiring on July 17, 2034.
• Nighan also disposed of 42,261 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing reflecting compensation practices. The acquisitions suggest confidence, but the disposal of shares tempers the positive view.

Positives

• The acquisition of restricted stock units, performance rights, and stock options aligns Nighan's interests with those of the shareholders.
• The vesting schedules for the restricted stock units and stock options encourage long-term commitment from Nighan.

Risks

• The value of the performance rights is contingent on AngioDynamics' total shareholder return relative to its peers, which may not be guaranteed.
• The stock options are only valuable if the stock price exceeds the exercise price of $7.40.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon continued employment and performance, aligning the executive's interests with the company's long-term success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common compensation practices in the medical device industry, used to incentivize and retain key executives.
• Vesting schedules of four years are typical for such grants, aligning with industry standards for long-term incentive plans.
• Performance-based equity awards, such as the performance rights granted to Nighan, are also increasingly common, linking executive compensation to company performance relative to peers.

Stakeholder Impact

• The transactions reported in the Form 4 filing may influence investor sentiment regarding AngioDynamics.
• The equity grants incentivize the executive to contribute to the company's long-term success, benefiting shareholders.

Key Dates